News & media

The Treatment Journey of a Patient with CLL

In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with…

Continue reading

What Is the Outlook for Older Patients with CLL?

The prognosis for patients with chronic lymphocytic leukemia (CLL) has seen recent improvements.

Continue reading

John N. Allan, MD, on Research Coming Out of ASH for CLL

The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill…

Continue reading

An Analysis of CLL in Adolescents and Young Adults

Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at…

Continue reading

Case Study: COVID-19 and the Coexistence of CLL

Many symptoms of SARS-CoV-2 (COVID-19) can be concealed due the coexistence of malignant…

Continue reading

Venclexta PBS listed as first line therapy for CLL patients unfit for chemotherapy

VENCLEXTA plus obinutuzumab is a combination, fixed duration therapy for previously untreated…

Continue reading

ASH 2020 CLL Daily Wrap-Up

Join Patient Power on Tuesday, December 8th at 4pm PT/7pm ET for a live recap of the latest chronic…

Continue reading

CLL and COVID-19: What Should Patients Know About Vaccines?

With the flu season approaching and whispers of a vaccine for COVID-19 in the works, CLL patients…

Continue reading

CLL Advocates NZ Newsletter Issue 6

Welcome to issue 6 of the CLL Advocates newsletter. This month's newsletter shares our latest…

Continue reading

NICE recommends new chemo-free chronic lymphocytic leukaemia treatment

More than 1,000 people each year could benefit from treatment with a combination of venetoclax and…

Continue reading

When and How CLL, SLL Should Be Treated

New treatment options are outperforming the “old-fashioned” chemotherapy regimens for patients with…

Continue reading

Dr. Awan on the Importance of Collaborative Care in CLL

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

Continue reading

Different Therapies and Modalities for Treatment of CLL in the Second Line

During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant…

Continue reading

CLL Advocates NZ Newsletter Issue 5

Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…

Continue reading

Novel Prognostic Model Predictive of Survival in Ibrutinib-Treated CLL

While there are existing prognostic indices, none specifically evaluate for criteria known to be…

Continue reading

CLL Advocates NZ Launches a New Zealand Patient Guide

CLL Advocates is pleased to announce the official launch of it's Guide for Patients in New Zealand.…

Continue reading

Dr. Davids on Factors to Inform Treatment Selection in CLL

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients…

Continue reading

The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with…

Continue reading

CLL Advocates NZ Newsletter Issue 4

Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…

Continue reading

Triple Therapy for CLL Shows Promise in Phase 2 Trial

Results from a phase 2 study of 3 oral targeted agents for chronic lymphocytic leukemia (CLL)…

Continue reading

The CLLANZ Inaugural CLL Seminar

Three top haematologists will present and take questions on CLL disease, diagnosis and management,…

Continue reading

Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors

Patients with CLL/small lymphocytic lymphoma (CLL/SLL) who had an MYD88 L265P mutation were…

Continue reading

Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia

CLL proliferate in secondary lymphatic organs where cancer cells engage in molecular and cellular…

Continue reading

Which Drug Therapy for CLL, Time-Limited or Continuous?

About two thirds of patients who are diagnosed with chronic lymphocytic leukemia (CLL) are…

Continue reading

EU approves Imbruvica plus rituximab in first-line CLL

There’s a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired…

Continue reading

4 October – CLL Treatments Today: What Should I Know?

Join us for a virtual town meeting for chronic lymphocytic leukemia (CLL) patients and family…

Continue reading

Clinical Trials Survey 2020

Please help Andrew give a powerful speech based on your experiences and thoughts around clinical…

Continue reading

Acalabrutinib Shows Promising Results for the Treatment of CLL

Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib…

Continue reading

Online webinar: Telling Others About My CLL Diagnosis

How do you tell family and friends that you have leukemia? Chronic Lymphocytic Leukemia (CLL)…

Continue reading

Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?

There’s a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired…

Continue reading